Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
Tolterodine [(R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine ] is a new potent and competitive muscarinic receptor antagonist developed for the treatment of urinary urge incontinence and other symptoms of overactive bladder. In vivo, tolterodine exhibits functional selectivity for the urinary bladder over salivary glands, a profile that cannot be explained in terms of selectivity for a single muscarinic receptor subtype. The aim of this study was to compare the in vitro and in vivo antimuscarinic profiles of tolterodine with those of muscarinic receptor antagonists with distinct receptor subtype-selectivity profiles: darifenacin [(S)-2-[1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl]-2,2-d iphenylacetamide; selective for muscarinic M3 receptors]; UH-AH 37 (6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-11H-dibenzo-[b ,e][1,4]diazepine-11-one; low affinity for muscarinic M2 receptors); and AQ-RA 741 (11-([4-[4-(diethylamino)butyl]-1-piperidinyl]acetyl)-5,11-dihydro-6H-py rido[2,3-b][1,4]benzodiazepine-6-one; high affinity for muscarinic M2 receptors). The in vitro profiles of these compounds were in agreement with previous reports; darifenacin and UH-AH 37 demonstrated selectivity for muscarinic M3/m3 over M2/m2 receptors, while the converse was observed for AQ-RA 741. In vivo, AQ-RA 741 was more potent (1.4-2.7-fold) in inhibiting urinary bladder contraction than salivation in the anaesthetised cat (i.e., a profile similar to that of tolterodine [2.5-3.3-fold]), while darifenacin and UH-AH 37 showed the reverse selectivity profile (0.6-0.8 and 0.4-0.5-fold, respectively). The results confirm that it is possible to separate the antimuscarinic effects on urinary bladder and salivary glands in vivo. The data on UH-AH 37 and darifenacin support the view that a selectivity for muscarinic M3/m3 over M2/m2 receptors may result in a more pronounced effect on salivation than on bladder contraction. The data on AQ-RA 741 may indicate that muscarinic M2/m2 receptors may have a role in bladder contraction.
Gillberg
P G
PG
Department of Pharmacology, Pharmacia and Upjohn, Uppsala, Sweden.
Sundquist
S
S
Nilvebrant
L
L
D000818:Animals; D001559:Benzhydryl Compounds / Q000378:metabolism* / Q000494:pharmacology*; D001570:Benzodiazepinones / Q000494:pharmacology; D001572:Benzofurans / Q000494:pharmacology; D016466:CHO Cells; D002415:Cats; D002540:Cerebral Cortex / Q000378:metabolism; D003408:Cresols / Q000378:metabolism* / Q000494:pharmacology*; D006224:Cricetinae; D003984:Dibenzazepines; D004558:Electric Stimulation; D005260:Female; D006168:Guinea Pigs; D008297:Male; D018727:Muscarinic Antagonists / Q000378:metabolism* / Q000494:pharmacology*; D009119:Muscle Contraction; D009130:Muscle, Smooth / Q000187:drug effects* / Q000502:physiology; D009206:Myocardium / Q000378:metabolism; D010665:Phenylpropanolamine; D010880:Piperidines / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000378:metabolism*; D012463:Saliva / Q000378:metabolism; D012469:Salivary Glands / Q000187:drug effects* / Q000378:metabolism; D000068737:Tolterodine Tartrate; D001743:Urinary Bladder / Q000187:drug effects* / Q000378:metabolism
D001559:Benzhydryl Compounds; D001570:Benzodiazepinones; D001572:Benzofurans; D003408:Cresols; D003984:Dibenzazepines; D018727:Muscarinic Antagonists; D010880:Piperidines; D011759:Pyrrolidines; D011976:Receptors, Muscarinic; C059904:UH-AH 37; C069054:AQ-RA 741; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C101207:darifenacin